In a milestone for national public health, Ilya laboratory Announced the launch of a Semaglutide Specially authorized for treatment Of excess weight and obesitydesigned with a true concept of accessibility and affordability.
This innovation comes at a critical time: In Argentina, more than 61% of adults are overweight or obese. Until today, internationally approved drug treatments have been a privilege for a few people due to their high costs. Elea is radically modifying this model with nationally manufactured technology and a pricing strategy that significantly lowers barriers to entry.
More than just aesthetics: responding to a health emergency
Obesity is a previously recognized chronic, progressive, multifactorial disease from As one of the greatest challenges of the twenty-first century. Far from being a matter of will or aesthetics, its effects are devastating, which compounds the problem Risk of developing type 2 diabetes, cardiovascular disease and various types of cancer.
“In Argentina and the region, a large number of people face a double stigma: the disease and the inability to treat it. “With the development of semaglutide in the obesity indication, we are taking a critical step to restore dignity and real choices to those with this condition.”male Dr. Matthias DeBrate, Director of Medical Affairs Elijah.
Scientific evidence: What do the studies say?
Semaglutide (a GLP-1 analog) acts on the appetite and gastric emptying centers in the brain, generating satiety and promoting sustained weight loss. Clinical results support its effectiveness:
- Weight loss: In STEP studies, patients achieved a greater than 18% reduction in body weight.
- Heart protection: The SELECT study (over 17,000 participants) showed that it reduces the risk of death from cardiovascular disease, heart attack and stroke by 20%.
- Comorbidities: It helps in treating associated conditions such as fatty liver, high blood pressure, and metabolic syndrome.
Expert voice
The arrival of this treatment option has led to a consensus among specialists:
“GLP-1 has revolutionized the clinical approach, and today this revolution reaches all social classes. This is not just a release, it is an act of health justice“Highlight Roxana Ratoa cardiologist in the Ilya laboratory.
For her part, Dr. said: Fabiana VasquezThe specialist in internal medicine, nutrition and diabetes, Minnesota: 86573, noted that “obesity is a multifactorial chronic disease that has a tremendous impact on the health of Argentines. In recent years We have a very big breakthrough: semaglutideA drug that acts on the appetite centers in the brain, which enhances satiety and helps regulate food intake.
This is important to note It is not a “quick fix” or substitute for healthy eating or physical activity.. It is indicated within a comprehensive plan and evaluation of each case and under medical supervision. Access and responsible use are key to ensuring safety and results.
“In my daily experience with patients, semaglutide has become an extremely valuable tool: It helps them naturally reduce portion sizes, more clearly recognize feelings of fullness, and make healthier choices without as much internal conflict. “This does not replace food support, but it facilitates the process and allows them to pursue changes that were previously difficult or unachievable.”
For her part, Dr. Virginia BusnelliMD, Nutrition and Obesity, MN: 110,351 Adds: “In daily practice, semaglutide has proven itself as an extremely valuable tool within a comprehensive approach to obesity:“It allows clinically significant and sustainable weight loss, improves cardio-metabolic indicators such as blood glucose, blood pressure, lipid profile and fatty liver, and has been shown to reduce the risk of cardiovascular disease in people with obesity.”
Thus, “the arrival of semaglutide, developed and produced in the country, expands the therapeutic range available to health teams. It is not a magic solution or an alternative to changes in habits, but rather another option that allows us to adapt treatment to the real needs and possibilities of each person.”
Finally, Dr. Natalia Nakhon A medical specialist in internal medicine and nutrition, and Director of the Metabolism and Obesity Council of the Argentine Medical Association, MN: 101.075, concluded: “Obesity is associated with a significant deterioration in the quality of life. Its treatment requires a comprehensive and sustainable approach. SImaglutide 2.4 mg achieved significant reduction in body weight“L, clinically relevant along with significant improvements in cardiometabolic parameters.”
“Weight loss caused by semaglutide is associated with a reduction in mechanical overload of the joints, with a positive effect, especially on the knees and hips. Studies have shown a reduction in pain, an improvement in physical function and an increase in mobility, which contributes to increased independence and reduced disability,” he added.
In addition, Improvements in measures of health-related quality of life (HRQoL) have been reported, including increased vitality, better body awareness, better functional ability, and reduced associated symptoms such as fatigue and shortness of breath during daily activities.
Semaglutide is prescribed under medical supervision and is an effective therapeutic tool within an integrated multidisciplinary approach Nutritional interventions, physical activity and lifestyle modifications, Improving clinical outcomes and promoting continued improvement in the quality of life of people with obesity.”
Innovate with purpose
The new medication is delivered in prefilled syringes for weekly subcutaneous administration, making it easier to administer. With more than 85 years of history, with this launch Laboratorio Elea strengthens its leadership in the field of metabolic diseases, reaffirming that innovation only makes sense if it reaches those who need it.
Master data
- epidemicObesity increased by approximately 75% between 2005 and 2018 in Argentina.
- impact: It is responsible for 44% of type 2 diabetes cases.
- Deaths: Worldwide, it causes more than 4 million deaths annually.
- solution: Semaglutide provides the largest current evidence of cardiovascular benefits